BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29883836)

  • 1. Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC.
    Yegya-Raman N; Wang K; Kim S; Reyhan M; Deek MP; Sayan M; Li D; Patel M; Malhotra J; Aisner J; Marks LB; Jabbour SK
    J Thorac Oncol; 2018 Oct; 13(10):1508-1518. PubMed ID: 29883836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
    Wang K; Eblan MJ; Deal AM; Lipner M; Zagar TM; Wang Y; Mavroidis P; Lee CB; Jensen BC; Rosenman JG; Socinski MA; Stinchcombe TE; Marks LB
    J Clin Oncol; 2017 May; 35(13):1387-1394. PubMed ID: 28113017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer.
    Wang K; Pearlstein KA; Patchett ND; Deal AM; Mavroidis P; Jensen BC; Lipner MB; Zagar TM; Wang Y; Lee CB; Eblan MJ; Rosenman JG; Socinski MA; Stinchcombe TE; Marks LB
    Radiother Oncol; 2017 Nov; 125(2):293-300. PubMed ID: 29050957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric Predictors of Cardiotoxicity in Thoracic Radiotherapy for Lung Cancer.
    Borkenhagen JF; Bergom C; Rapp CT; Klawikowski SJ; Rein LE; Gore EM
    Clin Lung Cancer; 2019 Nov; 20(6):435-441. PubMed ID: 31303452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation.
    Yegya-Raman N; Ho Lee S; Friedes C; Wang X; Iocolano M; Kegelman TP; Duan L; Li B; Berlin E; Kim KN; Doucette A; Denduluri S; Levin WP; Cengel KA; Cohen RB; Langer CJ; Kevin Teo BK; Zou W; O'Quinn RP; Deasy JO; Bradley JD; Sun L; Ky B; Xiao Y; Feigenberg SJ
    Radiother Oncol; 2024 Jan; 190():110005. PubMed ID: 37972736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart substructural dosimetric parameters and risk of cardiac events after definitive chemoradiotherapy for stage III non-small cell lung cancer.
    Jang BS; Cha MJ; Kim HJ; Oh S; Wu HG; Kim E; Kim BH; Kim JS; Chang JH
    Radiother Oncol; 2020 Nov; 152():126-132. PubMed ID: 33058951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
    Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
    J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications.
    Eblan MJ; Corradetti MN; Lukens JN; Xanthopoulos E; Mitra N; Christodouleas JP; Grover S; Fernandes AT; Langer CJ; Evans TL; Stevenson J; Rengan R; Apisarnthanarax S
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):175-81. PubMed ID: 22658442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of oesophageal radiation dose volume metrics, neutropenia and acute radiation oesophagitis in patients receiving chemoradiotherapy for non-small cell lung cancer.
    Everitt S; Duffy M; Bressel M; McInnes B; Russell C; Sevitt T; Ball D
    Radiat Oncol; 2016 Feb; 11():20. PubMed ID: 26864559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer.
    Atkins KM; Rawal B; Chaunzwa TL; Lamba N; Bitterman DS; Williams CL; Kozono DE; Baldini EH; Chen AB; Nguyen PL; D'Amico AV; Nohria A; Hoffmann U; Aerts HJWL; Mak RH
    J Am Coll Cardiol; 2019 Jun; 73(23):2976-2987. PubMed ID: 31196455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.
    Dess RT; Sun Y; Matuszak MM; Sun G; Soni PD; Bazzi L; Murthy VL; Hearn JWD; Kong FM; Kalemkerian GP; Hayman JA; Ten Haken RK; Lawrence TS; Schipper MJ; Jolly S
    J Clin Oncol; 2017 May; 35(13):1395-1402. PubMed ID: 28301264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and dose-volume histogram parameters associated with the development of pleural effusions in non-small cell lung cancer patients treated with chemoradiation therapy.
    Deek MP; Nagarajan S; Kim S; Ahmed I; Paul S; Scher ED; Listo M; Chen A; Aisner J; Hussain S; Haffty BG; Jabbour SK
    Acta Oncol; 2016 Aug; 55(8):1029-35. PubMed ID: 27219912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
    Tembhekar AR; Wright CL; Daly ME
    Clin Lung Cancer; 2017 May; 18(3):293-298. PubMed ID: 28089158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac Irradiation Predicts Activity Decline in Patients Receiving Concurrent Chemoradiation for Locally Advanced Lung Cancer.
    Paul S; Bodner WR; Garg M; Tang J; Ohri N
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):597-601. PubMed ID: 32497682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
    Singh AK; Lockett MA; Bradley JD
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of induction chemotherapy on the dosimetric parameters of subsequent radiotherapy: an investigation of 30 consecutive patients with locally-advanced non-small cell lung cancer and modern radiation planning techniques.
    Grant JD; Sobremonte A; Hillebrandt E; Allen PK; Gomez DR
    Radiat Oncol; 2015 Jan; 10():32. PubMed ID: 25636372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.
    Nieder C; Imingen KS; Mannsåker B; Yobuta R; Haukland E
    Radiat Oncol; 2020 May; 15(1):91. PubMed ID: 32357936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study.
    Yue J; Shi Q; Xu T; Jeter M; Chen TY; Komaki R; Gomez DR; Pan T; Cleeland CS; Liao Z; Wang XS
    Qual Life Res; 2018 Jun; 27(6):1563-1570. PubMed ID: 29549533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer.
    Atkins KM; Chaunzwa TL; Lamba N; Bitterman DS; Rawal B; Bredfeldt J; Williams CL; Kozono DE; Baldini EH; Nohria A; Hoffmann U; Aerts HJWL; Mak RH
    JAMA Oncol; 2021 Feb; 7(2):206-219. PubMed ID: 33331883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy.
    Atkins KM; Bitterman DS; Chaunzwa TL; Kozono DE; Baldini EH; Aerts HJWL; Tamarappoo BK; Hoffmann U; Nohria A; Mak RH
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1473-1479. PubMed ID: 33713743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.